Recursion Pharmaceuticals is using AI and machine learning to transform drug discovery, aiming to reduce costs and speed up development. The acquisition of Exscientia enhances its pipeline and partnerships, potentially leading to $20 billion in milestone payments. Despite some clinical trial setbacks, the company's innovative platform and strategic partnerships support a 'Buy' rating for long-term investors willing to take on high risk.